DIAGNOS Completes FDA Medical Device Registration Renewal

BROSSARD, Quebec, April 01, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that the annual registration for its medical device establishment with the U.S. Food and Drug Administration (FDA) has been successfully completed.

DIAGNOS Inc., a well-known entity in the healthcare technology space, announced a significant milestone in its operations by successfully completing the renewal of its Medical Device Establishment Registration with the U.S. Food and Drug Administration (FDA). This registration is crucial for companies that manufacture, process, pack, or hold medical devices intended for commercial distribution in the United States. The FDA requires all medical device establishments engaged in such activities to register with the agency to ensure compliance with applicable regulations.

The successful renewal signifies DIAGNOS's commitment to maintaining regulatory standards in its operational processes. This is particularly relevant as the company continues to innovate and expand its portfolio of diagnostic solutions. With this registration, DIAGNOS reaffirms its adherence to FDA guidelines, ensuring that its products meet the necessary safety and efficacy criteria required for market access in the U.S.

As a leader in medical technology, DIAGNOS specializes in innovative diagnostic solutions that enhance healthcare outcomes. The renewal not only allows the company to continue its operations within the U.S. market but also sends a positive signal to potential partners and customers regarding the company's dedication to compliance and quality assurance. Every device that DIAGNOS brings to market is subject to thorough scrutiny, echoing the company’s ethos of providing only the best and most reliable diagnostic solutions.

The FDA’s registration plays a vital role in the healthcare landscape, ensuring that only establishments that have proven capabilities in producing safe medical devices can operate. Through its successful renewal, DIAGNOS is positioned to not only meet current demands but also to explore opportunities for future growth and partnership in various healthcare sectors.

This achievement comes at a time when medical technology firms are increasingly scrutinized for their compliance with regulatory frameworks. It highlights DIAGNOS's proactive approach in fulfilling its regulatory obligations long before the expiration of its previous registration, reflecting its operational readiness and foresight in strategic planning.

Furthermore, maintaining active registration with the FDA allows DIAGNOS to bolster its reputation, attract investment, and potentially facilitate collaborations with other industry players. As the healthcare industry continues to evolve, having a solid foundation of compliance remains crucial for any company looking to thrive in this competitive environment.

In conclusion, DIAGNOS's successful renewal of its FDA Medical Device Establishment Registration is not only a bureaucratic triumph but a testament to the company's operational integrity and commitment to delivering high-quality medical devices. With a renewed focus on compliance and a robust product lineup, DIAGNOS is well-equipped to advance in the healthcare technology field.